RAAPID, an AI-powered risk adjustment company, announced it has secured an extension to its Series-A funding round with participation from UPMC Enterprises, the innovation and venture arm of UPMC. The investment builds on prior backing from M12, Microsoft’s venture fund, and is aimed at accelerating the expansion of RAAPID’s Clinical AI Platform.
The company focuses on applying Neuro-Symbolic AI to medical coding and risk adjustment, particularly for Medicare Advantage plans, accountable care organizations, and health systems. Its platform is designed to improve accuracy and compliance by linking diagnoses directly to encounter-based clinical evidence while generating audit-ready documentation.
RAAPID’s approach comes at a time when regulatory scrutiny around risk adjustment is intensifying. Increased enforcement actions, RADV audits, and investigations have prompted healthcare organizations to prioritize compliance-first solutions that ensure diagnoses are clinically supported, traceable, and defensible under audit conditions.
The platform supports both additions and deletions of diagnostic codes and is built to meet evolving regulatory expectations for transparency and explainability. It is deployed primarily on Microsoft Azure, allowing customers to maintain data sovereignty within their existing cloud environments and align spending with existing Azure commitments. The company also highlighted its HITRUST certification and SOC 2 compliance as indicators of its focus on security and regulatory standards.
The partnership with UPMC Enterprises is expected to enable co-development opportunities and further innovation in clinical AI applications for healthcare compliance and risk adjustment workflows. RAAPID aims to position its platform as a unified alternative to fragmented legacy systems across retrospective, prospective, and audit-focused use cases.
KEY QUOTES
“Neuro-Symbolic AI gives coders and compliance teams something legacy platforms do not: a transparent, clinician-grounded evidence trail behind every diagnosis. When an organization with UPMC’s depth of clinical and operational expertise conducts that level of evaluation and then decides to back your technology, it says something the market should pay attention to.”
Chetan Parikh, Founder And CEO Of RAAPID
“At UPMC Enterprises, we invest in innovations that have the potential to solve health care’s most complex problems. RAAPID’s technology aligns with this mission, and we look forward to co-developing solutions that address today’s regulatory expectations with responsible, transparent use of AI for risk adjustment.”
Matt Grant, Vice President At UPMC Enterprises
